Design, Synthesis, and Evaluation of Chalcone Derivatives as Multifunctional Agents against Alzheimer's Disease. 2021

Xiao-Qin Wang, and Lu-Yi Zhou, and Ren-Xian Tan, and Guo-Peng Liang, and Si-Xian Fang, and Wei Li, and Mei Xie, and Yu-Hao Wen, and Jia-Qiang Wu, and Yi-Ping Chen
School of Pharmacy, Guangdong Medical University, Dongguan, 523808, Guangdong, China.

Fifteen chalcone derivatives 3a-3o were synthesized, and evaluated as multifunctional agents against Alzheimer's disease. In vitro studies revealed that these compounds inhibited self-induced Aβ1-42 aggregation effectively ranged from 45.9-94.5 % at 20 μM, and acted as potential antioxidants. Their structure-activity relationships were summarized. In particular, (2E)-3-[4-(dimethylamino)phenyl]-1-(pyridin-2-yl)prop-2-en-1-one (3g) exhibited an excellent inhibitory activity of 94.5 % at 20 μM, and it could disassemble the self-induced Aβ1-42 aggregation fibrils with ratio of 57.1 % at 20 μM concentration. In addition, compound 3g displayed good chelating ability for Cu2+ , and could effectively inhibit and disaggregate Cu2+ -induced Aβ aggregation. Moreover, compound 3g exerted low cytotoxicity, significantly reversed Aβ1-42 -induced SH-SY5Y cell damage. More importantly, compound 3g remarkably ameliorated scopolamine-induced memory impairment in mice. In summary, all the results revealed compound 3g was a potential multifunctional agent for AD therapy.

UI MeSH Term Description Entries
D008569 Memory Disorders Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions. Memory Loss,Age-Related Memory Disorders,Memory Deficits,Memory Disorder, Semantic,Memory Disorder, Spatial,Memory Disorders, Age-Related,Retention Disorders, Cognitive,Semantic Memory Disorder,Spatial Memory Disorder,Age Related Memory Disorders,Age-Related Memory Disorder,Cognitive Retention Disorder,Cognitive Retention Disorders,Deficit, Memory,Deficits, Memory,Memory Deficit,Memory Disorder,Memory Disorder, Age-Related,Memory Disorders, Age Related,Memory Disorders, Semantic,Memory Disorders, Spatial,Memory Losses,Retention Disorder, Cognitive,Semantic Memory Disorders,Spatial Memory Disorders
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D003300 Copper A heavy metal trace element with the atomic symbol Cu, atomic number 29, and atomic weight 63.55. Copper-63,Copper 63
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000544 Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57) Acute Confusional Senile Dementia,Alzheimer's Diseases,Dementia, Alzheimer Type,Dementia, Senile,Presenile Alzheimer Dementia,Senile Dementia, Alzheimer Type,Alzheimer Dementia,Alzheimer Disease, Early Onset,Alzheimer Disease, Late Onset,Alzheimer Sclerosis,Alzheimer Syndrome,Alzheimer Type Senile Dementia,Alzheimer's Disease,Alzheimer's Disease, Focal Onset,Alzheimer-Type Dementia (ATD),Dementia, Presenile,Dementia, Primary Senile Degenerative,Early Onset Alzheimer Disease,Familial Alzheimer Disease (FAD),Focal Onset Alzheimer's Disease,Late Onset Alzheimer Disease,Primary Senile Degenerative Dementia,Senile Dementia, Acute Confusional,Alzheimer Dementias,Alzheimer Disease, Familial (FAD),Alzheimer Diseases,Alzheimer Type Dementia,Alzheimer Type Dementia (ATD),Alzheimers Diseases,Dementia, Alzheimer,Dementia, Alzheimer-Type (ATD),Familial Alzheimer Diseases (FAD),Presenile Dementia,Sclerosis, Alzheimer,Senile Dementia
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012601 Scopolamine An alkaloid from SOLANACEAE, especially DATURA and SCOPOLIA. Scopolamine and its quaternary derivatives act as antimuscarinics like ATROPINE, but may have more central nervous system effects. Its many uses include an anesthetic premedication, the treatment of URINARY INCONTINENCE and MOTION SICKNESS, an antispasmodic, and a mydriatic and cycloplegic. Hyoscine,Scopolamine Hydrobromide,Boro-Scopol,Isopto Hyoscine,Kwells,Scoburen,Scopace,Scopoderm TTS,Scopolamine Cooper,Transderm Scop,Transderm-V,Travacalm HO,Vorigeno,Boro Scopol,Transderm V
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs

Related Publications

Xiao-Qin Wang, and Lu-Yi Zhou, and Ren-Xian Tan, and Guo-Peng Liang, and Si-Xian Fang, and Wei Li, and Mei Xie, and Yu-Hao Wen, and Jia-Qiang Wu, and Yi-Ping Chen
April 2021, European journal of medicinal chemistry,
Xiao-Qin Wang, and Lu-Yi Zhou, and Ren-Xian Tan, and Guo-Peng Liang, and Si-Xian Fang, and Wei Li, and Mei Xie, and Yu-Hao Wen, and Jia-Qiang Wu, and Yi-Ping Chen
January 2020, Bioorganic chemistry,
Xiao-Qin Wang, and Lu-Yi Zhou, and Ren-Xian Tan, and Guo-Peng Liang, and Si-Xian Fang, and Wei Li, and Mei Xie, and Yu-Hao Wen, and Jia-Qiang Wu, and Yi-Ping Chen
February 2018, MedChemComm,
Xiao-Qin Wang, and Lu-Yi Zhou, and Ren-Xian Tan, and Guo-Peng Liang, and Si-Xian Fang, and Wei Li, and Mei Xie, and Yu-Hao Wen, and Jia-Qiang Wu, and Yi-Ping Chen
August 2023, Drug development research,
Xiao-Qin Wang, and Lu-Yi Zhou, and Ren-Xian Tan, and Guo-Peng Liang, and Si-Xian Fang, and Wei Li, and Mei Xie, and Yu-Hao Wen, and Jia-Qiang Wu, and Yi-Ping Chen
May 2014, Bioorganic & medicinal chemistry letters,
Xiao-Qin Wang, and Lu-Yi Zhou, and Ren-Xian Tan, and Guo-Peng Liang, and Si-Xian Fang, and Wei Li, and Mei Xie, and Yu-Hao Wen, and Jia-Qiang Wu, and Yi-Ping Chen
December 2019, European journal of medicinal chemistry,
Xiao-Qin Wang, and Lu-Yi Zhou, and Ren-Xian Tan, and Guo-Peng Liang, and Si-Xian Fang, and Wei Li, and Mei Xie, and Yu-Hao Wen, and Jia-Qiang Wu, and Yi-Ping Chen
June 2019, Bioorganic chemistry,
Xiao-Qin Wang, and Lu-Yi Zhou, and Ren-Xian Tan, and Guo-Peng Liang, and Si-Xian Fang, and Wei Li, and Mei Xie, and Yu-Hao Wen, and Jia-Qiang Wu, and Yi-Ping Chen
December 2021, Journal of enzyme inhibition and medicinal chemistry,
Xiao-Qin Wang, and Lu-Yi Zhou, and Ren-Xian Tan, and Guo-Peng Liang, and Si-Xian Fang, and Wei Li, and Mei Xie, and Yu-Hao Wen, and Jia-Qiang Wu, and Yi-Ping Chen
November 2023, Chemical biology & drug design,
Xiao-Qin Wang, and Lu-Yi Zhou, and Ren-Xian Tan, and Guo-Peng Liang, and Si-Xian Fang, and Wei Li, and Mei Xie, and Yu-Hao Wen, and Jia-Qiang Wu, and Yi-Ping Chen
September 2019, European journal of medicinal chemistry,
Copied contents to your clipboard!